OncoMatch/Clinical Trials/NCT06815497
Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
Is NCT06815497 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Telmisartan for ovarian cancer.
Treatment: Telmisartan — The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy (carboplatin)
Platinum-resistant or refractory ovarian cancer (OC) defined as progression of disease on carboplatin or growth of disease as detected on computed tomography (CT) scan within 6 months of last platinum treatment
Cannot have received: (rituximab, amifostine)
Received rituximab or amifostine within 30 days prior to first telmisartan dose on this study
Cannot have received: (bevacizumab)
Exception: as part of their SOC chemotherapy regimen
Using bevacizumab as part of their SOC chemotherapy regimen
Lab requirements
Blood counts
ANC ≥1.5 x 10^9/L, platelet count ≥100 x 10^9/L, hemoglobin ≥8 g/dL without recent transfusion (within 2 weeks)
Kidney function
creatinine ≤ 1.5 x IULN or measured or calculated creatinine clearance ≥ 40 mL/min per institutional standard
Liver function
total bilirubin level ≥1.5 x institutional upper limit of normal (IULN), AST ≤ 2.5 x IULN, ALT ≤ 2.5 x IULN
Adequate organ and bone marrow reserve function as indicated by the following: Adequate hematological function, defined as absolute neutrophil count (ANC) ≥1.5 x 10^9/L, platelet count ≥100 x 10^9/L, and hemoglobin ≥8 g/dL without recent transfusion (defined as a transfusion that has occurred within 2 weeks of the hemoglobin measurement); Adequate liver function, defined as total bilirubin level ≥1.5 x institutional upper limit of normal (IULN), aspartate aminotransferase (AST) ≤ 2.5 x IULN, and alanine aminotransferase (ALT) ≤ 2.5 x IULN; Adequate renal function defined as creatinine ≤ 1.5 x IULN or measured or calculated creatinine clearance ≥ 40 mL/min per institutional standard. Assessment methods must be recorded.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth Hitchcock · Lebanon, New Hampshire
- Dartmouth-Hitchcock Manchester · Manchester, New Hampshire
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06815497 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior , disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages